GSK Transfers Liver Drug Rights to Alfasigma – TMT

GlaxoSmithKline (GSK.L) agreed to sell global rights to its experimental liver disease drug linerixibat to Italy’s Alfasigma for up to $690 million, as the British drugmaker refocuses its hepatology pipeline on larger market opportunities.

The deal allows GSK to monetize a late-stage asset while concentrating resources on broader liver disease treatments with greater commercial potential.

Key Takeaways

GSK receives $300 million upfront plus regulatory milestone payments
Linerixibat awaits FDA approval decision by March 24, 2026
Deal sharpens GSK focus on hepatitis B treatments

Market reaction & context

The transaction reflects pharmaceutical companies’ strategic pivot toward high-value therapeutic areas. GSK’s hepatology portfolio reshuffle follows similar moves by major drugmakers seeking to optimize their development pipelines for maximum return on investment ¹.

Alfasigma will pay GSK $300 million upfront, with an additional $100 million upon expected U.S. Food and Drug Administration approval by March 24. The Italian company could pay another $20 million for European Union and U.K. approvals, plus up to $270 million in sales-based milestones and tiered double-digit royalties ².

Drug details and market opportunity

Linerixibat targets cholestatic pruritus in primary biliary cholangitis (PBC), a debilitating internal itch affecting up to 90% of patients with the rare liver disease. The oral drug works by inhibiting bile acid reuptake, reducing circulation of itch-driving compounds ³.

The treatment met its primary endpoint in the phase three GLISTEN trial, showing significant improvement in itch symptoms over 24 weeks versus placebo. Linerixibat has received orphan drug designation in the United States, European Union and Japan ⁴.

Strategic rationale and management commentary

Tony Wood, GSK’s chief scientific officer, said the agreement allows the company to focus on its next wave of liver disease innovation.

“This agreement sharpens GSK’s focus to deliver our next wave of liver disease innovation, including potential treatments for chronic hepatitis B, MASH and ALD, which account for two million deaths annually,” Wood said ⁵.

The deal fits Alfasigma’s hepatology strategy following its 2023 acquisition of Intercept Pharmaceuticals for $794 million. Francesco Balestrieri, Alfasigma’s chief executive, said the company’s “deep hepatology expertise and strong global footprint” position it well for linerixibat’s commercialization ⁶.

Competitive landscape

If approved, linerixibat could become the first treatment specifically targeting cholestatic pruritus in PBC patients. Mirum Pharmaceuticals is developing a competing IBAT inhibitor, volixibat, but that program remains in phase two trials with results not expected until 2027 ⁷.

The timing gives Alfasigma a potential multi-year head start in a specialized market with limited treatment options. Current first-line therapy cholestyramine shows variable efficacy and tolerability among patients ⁸.

Broader portfolio implications

GSK’s divestiture enables greater investment in larger hepatology opportunities including bepirovirsen for chronic hepatitis B, which posted positive phase three results in January 2026. The company also acquired Boston Pharmaceuticals’ efimosfermin for up to $2 billion last year ⁹.

The transaction is subject to regulatory clearances including Hart-Scott-Rodino Act approval in the United States. Completion is expected prior to the FDA’s March 24 decision date for linerixibat.

Not investment advice. For informational purposes only.